LONDON (Alliance News) - Biotechnology company PureTech Health PLC on Monday said it exclusively licenced the intellectual property behind a recent research publication in Nature Neuroscience.
The research identified the physical connection between cerebrospinal fluid and the lymphatic system. It also suggested that this connection could play a strong role in in neuroinflammatory conditions, such as multiple sclerosis, in which the body's immune cells attack the central nervous system.
Modulating this connection "has the potential to improve symptoms" of these kinds of diseases, PureTech said.
The underlying intellectual property is being developed by the biopharmaceutical company's internal division and research is being conducted by Jonathan Kipnis, a company collaborator & chair of the neuroscience department at the University of Virginia School of Medicine.
"This work further suggests that the lymphatic system plays a critical role in the central nervous system," said Kipnis.
"I look forward to working with PureTech Health as they further advance these findings to potentially improve intervention and treatment of neuroinflammatory disease," he added.
Shares in PureTech Health closed down 0.3% at 165.00 pence on Monday.
PureTech (PRTC)